Pancreatic Cancer Research

ResearcherAmsterdam University Medical CentersActive in the last 2 years

Martijn Ruben Meijerink

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1500-7294; OpenAlex author ID A5024066538. Sources: OpenAlex.

Their work

Papers
30 (first author 0, last author 12)
Trials
0
Grants
0
Labs led
2
Collaborators
55
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: 3 papers · 2018: 2 papers · 2019: 5 papers · 2020: 3 papers · 2021: 7 papers · 2022: 1 paper · 2023: 4 papers · 2024: 2 papers · 2025: 1 paper · 2026: 1 paper

Papers 30

  1. The European Multidisciplinary Evidence-Based Guideline on Pancreatic Cancer: Methodological Protocol. Co-author DOI 10.1002/gin2.70074↗
  2. Systemic immunomodulation by irreversible electroporation versus stereotactic ablative body radiotherapy in locally advanced pancreatic cancer: the CROSSFIRE t… Co-author DOI 10.1136/jitc-2024-010222↗
  3. MRI-guided stereotactic ablative body radiotherapy versus CT-guided percutaneous irreversible electroporation for locally advanced pancreatic cancer (CROSSFIRE… Last author DOI 10.1016/s2468-1253(24)00017-7↗
  4. Ablative treatments for locally advanced pancreatic cancer: the CROSSFIRE trial: Authors' reply. Last author DOI 10.1016/s2468-1253(24)00162-6↗
  5. Tissue Resistance Decrease during Irreversible Electroporation of Pancreatic Cancer as a Biomarker for the Adaptive Immune Response and Survival. Last author DOI 10.1016/j.jvir.2023.06.027↗
  6. Transcatheter CT arteriography-guided irreversible electroporation of locally advanced pancreatic adenocarcinoma: A pictorial essay. Last author DOI 10.1111/1754-9485.13535↗
  7. Correction: Stereotactic ablative radiotherapy or best supportive care in patients with localized pancreatic cancer not receiving chemotherapy and surgery (PAN… Co-author DOI 10.1186/s12885-023-10521-1↗
  8. Optimizing patient selection for stereotactic ablative radiotherapy in patients with locally advanced pancreatic cancer after initial chemotherapy - a single c… Co-author DOI 10.3389/fonc.2023.1149961↗
  9. Stereotactic ablative radiotherapy or best supportive care in patients with localized pancreatic cancer not receiving chemotherapy and surgery (PANCOSAR): a na… Co-author DOI 10.1186/s12885-022-10419-4↗
  10. Locally Advanced Pancreatic Cancer: Percutaneous Management Using Ablation, Brachytherapy, Intra-arterial Chemotherapy, and Intra-tumoral Immunotherapy. Last author DOI 10.1007/s11912-021-01057-3↗
  11. Treatment strategies and clinical outcomes in consecutive patients with locally advanced pancreatic cancer: A multicenter prospective cohort. Co-author DOI 10.1016/j.ejso.2020.11.137↗
  12. The treatment and survival of elderly patients with locally advanced pancreatic cancer: A post-hoc analysis of a multicenter registry. Co-author DOI 10.1016/j.pan.2020.11.012↗
  13. Radiofrequency ablation and chemotherapy versus chemotherapy alone for locally advanced pancreatic cancer (PELICAN): study protocol for a randomized controlled… Co-author DOI 10.1186/s13063-021-05248-y↗
  14. Locoregional Treatment of Metastatic Pancreatic Cancer Utilizing Resection, Ablation and Embolization: A Systematic Review. Co-author DOI 10.3390/cancers13071608↗
  15. Irreversible Electroporation and Nivolumab Combined with Intratumoral Administration of a Toll-Like Receptor Ligand, as a Means of In Vivo Vaccination for Meta… Last author DOI 10.3390/cancers13153902↗
  16. Pancreatic Cancer and Immunotherapy: A Clinical Overview. Co-author DOI 10.3390/cancers13164138↗
  17. Value of CT-Guided Percutaneous Irreversible Electroporation Added to FOLFIRINOX Chemotherapy in Locally Advanced Pancreatic Cancer: A Post Hoc Comparison. Last author DOI 10.1016/j.jvir.2020.02.024↗
  18. Irreversible Electroporation for Locally Advanced Pancreatic Cancer. Co-author DOI 10.1016/j.tvir.2020.100675↗
  19. Percutaneous Irreversible Electroporation in Locally Advanced and Recurrent Pancreatic Cancer (PANFIRE-2): A Multicenter, Prospective, Single-Arm, Phase II Stu… Last author DOI 10.1148/radiol.2019191109↗
  20. Exocrine pancreatic and enterocyte function in patients with advanced pancreatic cancer. Co-author DOI 10.1016/j.clnu.2018.12.005↗
  21. Identification of patients with locally advanced pancreatic cancer benefitting from plan adaptation in MR-guided radiation therapy. Co-author DOI 10.1016/j.radonc.2018.11.019↗
  22. Irreversible electroporation of locally advanced pancreatic cancer transiently alleviates immune suppression and creates a window for antitumor T cell activati… Co-author DOI 10.1080/2162402x.2019.1652532↗
  23. Needle-guided ablation of locally advanced pancreatic cancer: cytoreduction or immunomodulation by in vivo vaccination? Last author DOI 10.21037/cco.2019.10.05↗
  24. Locally Advanced Pancreatic Cancer: Work-Up, Staging, and Local Intervention Strategies. Co-author DOI 10.3390/cancers11070976↗
  25. Fecal Elastase Fails to Detect Steatorrhea in Patients With Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001020↗
  26. Locally Advanced Pancreatic Cancer: A Review of Local Ablative Therapies. Last author DOI 10.3390/cancers10010016↗
  27. MR and CT imaging characteristics and ablation zone volumetry of locally advanced pancreatic cancer treated with irreversible electroporation. Last author DOI 10.1007/s00330-016-4581-2↗
  28. Ablation of Locally Advanced Pancreatic Cancer with Percutaneous Irreversible Electroporation: Results of the Phase I/II PANFIRE Study. Last author DOI 10.1148/radiol.2016152835↗
  29. Assessment of Nutritional Status, Digestion and Absorption, and Quality of Life in Patients with Locally Advanced Pancreatic Cancer. Co-author DOI 10.1155/2017/6193765↗
  30. Phase I Clinical Trial to Determine the Feasibility and Maximum Tolerated Dose of Panitumumab to Standard Gemcitabine-Based Chemoradiation in Locally Advanced … Co-author DOI 10.1158/1078-0432.ccr-14-3364↗

Closest collaborators

The 25 strongest of 55 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hester J. Scheffer · 19 shared papers, 2017–2025 · strength 2.37
  2. Bart Geboers · 13 shared papers, 2019–2025 · strength 1.87
  3. Florentine E. F. Timmer · 10 shared papers, 2020–2025 · strength 1.57
  4. Anna M E Bruynzeel · 9 shared papers, 2015–2025 · strength 1.35
  5. Alette H. Ruarus · 10 shared papers, 2018–2025 · strength 1.23
  6. Tanja D. de Gruijl · 10 shared papers, 2017–2025 · strength 1.21
  7. Johanna W. Wilmink · 11 shared papers, 2015–2023 · strength 1.12
  8. Geert Kazemier M · 11 shared papers, 2015–2023 · strength 1.05
  9. Marc G. Besselink · 10 shared papers, 2017–2023 · strength 1.01
  10. Laurien G. P. H. Vroomen · 9 shared papers, 2017–2025 · strength 0.99
  11. Frank J. Lagerwaard · 6 shared papers, 2019–2025 · strength 0.91
  12. Izaak Quintus Molenaar · 6 shared papers, 2019–2023 · strength 0.60
  13. Hjalmar C. van Santvoort · 6 shared papers, 2019–2023 · strength 0.60
  14. Geertjan van Tienhoven · 5 shared papers, 2015–2023 · strength 0.56
  15. Deesje Doppenberg · 3 shared papers, 2022–2023 · strength 0.43
  16. Eva Versteijne · 3 shared papers, 2022–2023 · strength 0.43
  17. Krijn P. van Lienden · 5 shared papers, 2019–2021 · strength 0.43
  18. Bas Groot Koerkamp · 3 shared papers, 2019–2023 · strength 0.34
  19. Casper H.J. van Eijck · 3 shared papers, 2019–2023 · strength 0.34
  20. Marieke S. Walma · 4 shared papers, 2019–2021 · strength 0.33
  21. Lilly J. H. Brada · 4 shared papers, 2019–2021 · strength 0.33
  22. Marian A.E. de van der Schueren · 4 shared papers, 2017–2019 · strength 0.33
  23. Jill E. Witvliet-van Nierop · 4 shared papers, 2017–2019 · strength 0.33
  24. Nicolette Wierdsma · 3 shared papers, 2017–2019 · strength 0.27
  25. Hanneke W.M. van Laarhoven · 2 shared papers, 2022–2023 · strength 0.27

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.